Psoriasis Clinical Trials in Columbus

View 11 new treatments for Psoriasis in Columbus, OH near me. Every day, Power helps hundreds of Psoriasis patients connect with leading medical research.
View 14 trials in Columbus
Filter (14)

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, Bexley + 2 more

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 6 - 12 Weeks
Bristol-Myers Squibb
Study Director

ESK-001 for Psoriasis

Alumis Clinic, Gahanna + 1 more

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

JNJ-77242113 for Plaque Psoriasis

Janssen Clinic, Bexley + 1 more

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director

Certolizumab Pegol for Plaque Psoriasis

UCB Biopharma Clinic, Marion + 1 more

The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
UCB Cares
Study Director

TAK-279 for Plaque Psoriasis

Takeda Clinic, Bexley + 1 more

This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The goal is to find out if TAK-279 can reduce the skin problems better than other available treatments.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Study Director
Study Director

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, Columbus + 2 more

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director

Guselkumab for Psoriasis

Janssen Clinic, Bexley + 2 more

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Guselkumab for Plaque Psoriasis

Janssen Clinic, Bexley + 2 more

This trial is testing guselkumab, a medication that targets the immune system, on people with moderate plaque psoriasis affecting small areas and special sites. The drug helps reduce inflammation and rapid skin cell growth. Guselkumab has been approved for the treatment of moderate-to-severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

TAK-279 for Psoriasis

Takeda Clinic, Bexley + 1 more

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Study Director
Study Director

TAK-279 for Plaque Psoriasis

Takeda Clinic, Columbus + 1 more

This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Study Director
Study Director
Page 1 of 2

Frequently Asked Questions

How much do psoriasis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do psoriasis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in Columbus, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

What promising new drugs are being tested?

In Columbus, psoriasis research includes treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied are Guselkumab, Deucravacitinib, and Nivolumab.